Isoflurane anesthesia elicits protein pattern changes in rat hippocampus

Journal of Neurosurgical Anesthesiology

Volumn 22, Issue 2, 2010, Pages 144-154

  Kalenka, Armin ^a   Gross, Benjamin ^b   Maurer, Martin H ^b   Thierse, Hermann Josef ^a   Feldmann, Robert E ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Alzheimer disease; Isoflurane; Proteomics

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA ENOLASE; ALPHA INTERNEXIN; ALPHA3 INTEGRIN; BRAIN PROTEIN; COLLAPSIN RESPONSE MEDIATOR PROTEIN 2; CYCLIN DEPENDENT KINASE INHIBITOR 2C; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GLIAL FIBRILLARY ACIDIC PROTEIN; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 60; HEPATOCYTE NUCLEAR FACTOR 4ALPHA; I KAPPA B KINASE ALPHA; ISOFLURANE; MAGNESIUM; NEUROFILAMENT PROTEIN; NUCLEOSIDE PHOSPHORYLASE; PEROXIREDOXIN 2; PROTEIN TYROSINE KINASE; PROTEOME; PROTHROMBIN; SENESCENCE MARKER PROTEIN 2; SEPTIN 5; SOMATOMEDIN C; SUPPRESSOR OF CYTOKINE SIGNALING; SYNAPSIN I; TRANSCRIPTION FACTOR T BET; TRANSFORMING GROWTH FACTOR BETA1; UBIQUITIN THIOLESTERASE; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALZHEIMER DISEASE; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN MAPPING; CYTOSKELETON; DETOXIFICATION; DRUG MECHANISM; HIPPOCAMPUS; MALE; MASS SPECTROMETRY; NERVE CELL PLASTICITY; NEUROPATHOLOGY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RAT; STRESS; TWO DIMENSIONAL ELECTROPHORESIS;

ALZHEIMER DISEASE; ANESTHESIA, INHALATION; ANESTHETICS, INHALATION; ANIMALS; BRAIN MAPPING; CARBON DIOXIDE; CELL COMMUNICATION; COMPUTATIONAL BIOLOGY; CYTOSKELETON; DATABASES, GENETIC; HIPPOCAMPUS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; ISOFLURANE; MALE; METABOLIC DETOXICATION, DRUG; NERVE TISSUE PROTEINS; OXYGEN; PROTEOME; PULMONARY ALVEOLI; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION;

EID: 77949976470     PISSN: 08984921     EISSN: None     Source Type: Journal    
DOI: 10.1097/ANA.0b013e3181cb7cb8     Document Type: Article

References (58)

1. Lenz C, Rebel A, van Ackern K, et al. Local cerebral blood flow, local cerebral glucose utilization, and flow-metabolism coupling during sevoflurane versus isoflurane anesthesia in rats. Anesthesiology. 1998;89:1480-1488.
2. Hemmings HC Jr, Akabas MH, Goldstein PA, et al. Emerging molecular mechanisms of general anesthetic action. Trends Pharmacol Sci. 2005;26:503-510.
3. Eckenhoff RG. Promiscuous ligands and attractive cavities: how do the inhaled anesthetics work? Mol Interv. 2001;1:258-268.
4. Eckenhoff RG. Do specific or nonspecific interactions with proteins underlie inhalational anesthetic action? Mol Pharmacol. 1998;54: 610-615.
5. Futterer CD, Maurer MH, Schmitt A, et al. Alterations in rat brain proteins after desflurane anesthesia. Anesthesiology. 2004;100: 302-308.
6. Kalenka A, Hinkelbein J, Feldmann RE Jr, et al. The effects of sevoflurane anesthesia on rat brain proteins: a proteomic timecourse analysis. Anesth Analg. 2007;104:1129-1135.
7. Xi J, Liu R, Asbury GR, et al. Inhalational anesthetic-binding proteins in rat neuronal membranes. J Biol Chem. 2004;279:19628-19633.
8. Perouansky M. Liaisons dangereuses? General anaesthetics and long-term toxicity in the CNS. Eur J Anaesthesiol. 2007;24:107-115.
9. Ancelin ML, de Roquefeuil G, Ledesert B, et al. Exposure to anaesthetic agents, cognitive functioning and depressive symptomatology in the elderly. Br J Psychiatry. 2001;178:360-366.
10. Johnson T, Monk T, Rasmussen LS, et al. Postoperative cognitive dysfunction in middle-aged patients. Anesthesiology. 2002;96: 1351-1357.
11. Culley DJ, Baxter MG, Crosby CA, et al. Impaired acquisition of spatial memory 2 weeks after isoflurane and isoflurane-nitrous oxide anesthesia in aged rats. Anesth Analg. 2004;99:1393-1397.
12. Jevtovic-Todorovic V, Hartman RE, Izumi Y, et al. Early exposure to common anesthetic agents causes widespread neurodegeneration in the developing rat brain and persistent learning deficits. J Neurosci. 2003;23:876-882.
13. Carnini A, Eckenhoff MF, Eckenhoff RG. Interactions of volatile anesthetics with neurodegenerative-disease-associated proteins. Anesthesiol Clin. 2006;24:381-405.
14. Xie Z, Tanzi RE. Alzheimer,s disease and post-operative cognitive dysfunction. Exp Gerontol. 2006;41:346-359.
15. Fountoulakis M, Hardmaier R, Schuller E, et al. Differences in protein level between neonatal and adult brain. Electrophoresis. 2000;21:673-678.
16. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
17. Maurer MH. Software analysis of two-dimensional electrophoretic gels in proteomic experiments. Current Bioinformatics. 2006;1: 255-262.
18. Nasu I, Yokoo N, Takaoka S, et al. The dose-dependent effects of isoflurane on outcome from severe forebrain ischemia in the rat. Anesth Analg. 2006;103:413-418.
19. Schonberger SJ, Edgar PF, Kydd R, et al. Proteomic analysis of the brain in Alzheimer,s disease: molecular phenotype of a complex disease process. Proteomics. 2001;1:1519-1528.
20. Sultana R, Boyd-Kimball D, Cai J, et al. Proteomics analysis of the Alzheimer,s disease hippocampal proteome. J Alzheimers Dis. 2007; 11:153-164.
21. Sizova D, Charbaut E, Delalande F, et al. Proteomic analysis of brain tissue from an Alzheimer,s disease mouse model by twodimensional difference gel electrophoresis. Neurobiol Aging. 2007;28: 357-370.
22. Pan JZ, Xi J, Tobias JW, et al. Halothane binding proteome in human brain cortex. J Proteome Res. 2007;6:582-592.
23. Culley DJ, Yukhananov RY, Xie Z, et al. Altered hippocampal gene expression 2 days after general anesthesia in rats. Eur J Pharmacol. 2006;549:71-78.
24. Pan JZ, Wei H, Hecker JG, et al. Rat brain DNA transcript profile of halothane and isoflurane exposure. Pharmacogenet Genomics. 2006;16:171-182.
25. Sakamoto A, Imai J, Nishikawa A, et al. Influence of inhalation anesthesia assessed by comprehensive gene expression profiling. Gene. 2005;356:39-48.
26. Rampil IJ, Moller DH, Bell AH. Isoflurane modulates genomic expression in rat amygdala. Anesth Analg. 2006;102:1431-1438.
27. Alfonso J, Pollevick GD, Castensson A, et al. Analysis of gene expression in the rat hippocampus using Real Time PCR reveals high inter-individual variation in mRNA expression levels. J Neurosci Res. 2002;67:225-234.
28. Clarke R, Ressom HW, Wang A, et al. The properties of highdimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer. 2008;8:37-49.
29. Liem EB, Lin CM, Suleman MI, et al. Anesthetic requirement is increased in redheads. Anesthesiology. 2004;101:279-283.
30. Messier C, Gagnon M. Glucose regulation and cognitive functions: relation to Alzheimer,s disease and diabetes. Behav Brain Res. 1996;75:1-11.
31. Gong B, Cao Z, Zheng P, et al. Ubiquitin hydrolase Uch-L1 rescues beta-amyloid-induced decreases in synaptic function and contextual memory. Cell. 2006;126:775-788.
32. Sakurai M, Sekiguchi M, Zushida K, et al. Reduction in memory in passive avoidance learning, exploratory behaviour and synaptic plasticity in mice with a spontaneous deletion in the ubiquitin C-terminal hydrolase L1 gene. Eur J Neurosci. 2008;27:691-701.
33. Veereshwarayya V, Kumar P, Rosen KM, et al. Differential effects of mitochondrial heat shock protein 60 and related molecular chaperones to prevent intracellular beta-amyloid-induced inhibition of complex IV and limit apoptosis. J Biol Chem. 2006;281: 29468-29478.
34. Dou F, Netzer WJ, Tanemura K, et al. Chaperones increase association of tau protein with microtubules. Proc Natl Acad Sci USA. 2003;100:721-726.
35. Lee VM, Goedert M, Trojanowski JQ. Neurodegenerative tauopathies. Annu Rev Neurosci. 2001;24:1121-1159.
36. Li YJ, Oliveira SA, Xu P, et al. Glutathione S-transferase omega-1 modifies age-at-onset of Alzheimer disease and Parkinson disease. Hum Mol Genet. 2003;12:3259-3267.
37. Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer,s disease. Neurobiol Aging. 2001;22:903-908.
38. Giri RK, Selvaraj SK, Kalra VK. Amyloid peptide-induced cytokine and chemokine expression in THP-1 monocytes is blocked by small inhibitory RNA duplexes for early growth response-1 messenger RNA. J Immunol. 2003;170:5281-5294.
39. Krapfenbauer K, Engidawork E, Cairns N, et al. Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders. Brain Res. 2003;967:152-160.
40. Octave JN, Essalmani R, Tasiaux B, et al. The role of presenilin-1 in the gamma-secretase cleavage of the amyloid precursor protein of Alzheimer,s disease. J Biol Chem. 2000;275:1525-1528.
41. Cao X, Sudhof TC. A transcriptionally correction of transcriptively active complex of APP with Fe65 and histone acetyltransferase Tip60. Science. 2001;293:115-120.
42. Muller T, Concannon CG, Ward MW, et al. Modulation of gene expression and cytoskeletal dynamics by the amyloid precursor protein intracellular domain (AICD).Mol Biol Cell. 2007;18:201-210.
43. Yu C, Kim SH, Ikeuchi T, et al. Characterization of a presenilinmediated amyloid precursor protein carboxyl-terminal fragment gamma. Evidence for distinct mechanisms involved in gamma - secretase processing of the APP and Notch1 transmembrane domains. J Biol Chem. 2001;276:43756-43760.
44. Hardy J. The Alzheimer family of diseases: many etiologies, one pathogenesis? Proc Natl Acad Sci USA. 1997;94:2095-2097.
45. Liang G, Wang Q, Li Y, et al. A presenilin-1 mutation renders neurons vulnerable to isoflurane toxicity. Anesth Analg. 2008;106: 492-500, table of contents.
46. Yoshida H, Watanabe A, Ihara Y. Collapsin response mediator protein-2 is associated with neurofibrillary tangles in Alzheimer,s disease. J Biol Chem. 1998;273:9761-9768.
47. Yoshimura T, Arimura N, Kaibuchi K. Molecular mechanisms of axon specification and neuronal disorders. Ann N Y Acad Sci. 2006; 1086:116-125.
48. Cairns NJ, Uryu K, Bigio EH, et al. alpha-Internexin aggregates are abundant in neuronal intermediate filament inclusion disease (NIFID) but rare in other neurodegenerative diseases. Acta Neuropathol. 2004;108:213-223.
49. Dickson TC, Chuckowree JA, Chuah MI, et al. alpha-Internexin immunoreactivity reflects variable neuronal vulnerability in Alzheimer,s disease and supports the role of the beta-amyloid plaques in inducing neuronal injury. Neurobiol Dis. 2005;18:286-295.
50. Dawson GR, Seabrook GR, Zheng H, et al. Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein. Neuroscience. 1999;90:1-13.
51. Ho L, Guo Y, Spielman L, et al. Altered expression of a-type but not b-type synapsin isoform in the brain of patients at high risk for Alzheimer,s disease assessed by DNA microarray technique. Neurosci Lett. 2001;298:191-194.
52. Kinoshita A, KinoshitaM, Akiyama H, et al. Identification of septins in neurofibrillary tangles in Alzheimer,s disease. Am J Pathol. 1998; 153:1551-1560.
53. Parvathenani LK, Tertyshnikova S, Greco CR, et al. P2×7 mediates superoxide production in primary microglia and is upregulated in a transgenic mouse model of Alzheimer,s disease. J Biol Chem. 2003;278:13309-13317.
54. Rampe D, Wang L, Ringheim GE. P2×7 receptor modulation of beta-amyloid- and LPS-induced cytokine secretion from human macrophages and microglia. J Neuroimmunol. 2004;147:56-61.
55. Moore D, Iritani S, Chambers J, et al. Immunohistochemical localization of the P2Y1 purinergic receptor in Alzheimer,s disease. Neuroreport. 2000;11:3799-3803.
56. Tumini E, Porcellini E, Chiappelli M, et al. The G51S purine nucleoside phosphorylase polymorphism is associated with cognitive decline in Alzheimer,s disease patients. Hum Psychopharmacol. 2007;22:75-80.
57. Eckenhoff RG, Johansson JS, Wei H, et al. Inhaled anesthetic enhancement of amyloid-beta oligomerization and cytotoxicity. Anesthesiology. 2004;101:703-709.
58. Fodale V, Quattrone D, Trecroci C, et al. Alzheimer,s disease and anaesthesia: implications for the central cholinergic system. Br J Anaesth. 2006;97:445-452.